Fibroma medical therapy: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Line 5: Line 5:
===Uterine fibroma===
===Uterine fibroma===


At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor.<ref name="SabryAl-Hendy2012">{{cite journal|last1=Sabry|first1=Mohamed|last2=Al-Hendy|first2=Ayman|title=Medical Treatment of Uterine Leiomyoma|journal=Reproductive Sciences|volume=19|issue=4|year=2012|pages=339–353|issn=1933-7191|doi=10.1177/1933719111432867}}</ref><ref name="DonnezDolmans2016">{{cite journal|last1=Donnez|first1=Jacques|last2=Dolmans|first2=Marie-Madeleine|title=Uterine fibroid management: from the present to the future|journal=Human Reproduction Update|volume=22|issue=6|year=2016|pages=665–686|issn=1355-4786|doi=10.1093/humupd/dmw023}}</ref><ref name="MurjiWhitaker2017">{{cite journal|last1=Murji|first1=Ally|last2=Whitaker|first2=Lucy|last3=Chow|first3=Tiffany L|last4=Sobel|first4=Mara L|title=Selective progesterone receptor modulators (SPRMs) for uterine fibroids|journal=Cochrane Database of Systematic Reviews|year=2017|issn=14651858|doi=10.1002/14651858.CD010770.pub2}}</ref><ref name="ArenaZupi2011">{{cite journal|last1=Arena|first1=Saverio|last2=Zupi|first2=Errico|title=Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option|journal=Women's Health|volume=7|issue=2|year=2011|pages=143–146|issn=1745-5065|doi=10.2217/WHE.11.1}}</ref><ref name="De LeoMorgante2002">{{cite journal|last1=De Leo|first1=Vincenzo|last2=Morgante|first2=Giuseppe|last3=La Marca|first3=Antonio|last4=Musacchio|first4=Maria Concetta|last5=Sorace|first5=Massimo|last6=Cavicchioli|first6=Chiara|last7=Petraglia|first7=Felice|title=A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas|journal=Drug Safety|volume=25|issue=11|year=2002|pages=759–779|issn=0114-5916|doi=10.2165/00002018-200225110-00002}}</ref><ref name="SankaranManyonda2008">{{cite journal|last1=Sankaran|first1=Srividhya|last2=Manyonda|first2=Isaac T.|title=Medical management of fibroids|journal=Best Practice & Research Clinical Obstetrics & Gynaecology|volume=22|issue=4|year=2008|pages=655–676|issn=15216934|doi=10.1016/j.bpobgyn.2008.03.001}}</ref>
At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor.<ref name="SabryAl-Hendy2012">{{cite journal|last1=Sabry|first1=Mohamed|last2=Al-Hendy|first2=Ayman|title=Medical Treatment of Uterine Leiomyoma|journal=Reproductive Sciences|volume=19|issue=4|year=2012|pages=339–353|issn=1933-7191|doi=10.1177/1933719111432867}}</ref><ref name="DonnezDolmans2016">{{cite journal|last1=Donnez|first1=Jacques|last2=Dolmans|first2=Marie-Madeleine|title=Uterine fibroid management: from the present to the future|journal=Human Reproduction Update|volume=22|issue=6|year=2016|pages=665–686|issn=1355-4786|doi=10.1093/humupd/dmw023}}</ref><ref name="MurjiWhitaker2017">{{cite journal|last1=Murji|first1=Ally|last2=Whitaker|first2=Lucy|last3=Chow|first3=Tiffany L|last4=Sobel|first4=Mara L|title=Selective progesterone receptor modulators (SPRMs) for uterine fibroids|journal=Cochrane Database of Systematic Reviews|year=2017|issn=14651858|doi=10.1002/14651858.CD010770.pub2}}</ref><ref name="ArenaZupi2011">{{cite journal|last1=Arena|first1=Saverio|last2=Zupi|first2=Errico|title=Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option|journal=Women's Health|volume=7|issue=2|year=2011|pages=143–146|issn=1745-5065|doi=10.2217/WHE.11.1}}</ref><ref name="De LeoMorgante2002">{{cite journal|last1=De Leo|first1=Vincenzo|last2=Morgante|first2=Giuseppe|last3=La Marca|first3=Antonio|last4=Musacchio|first4=Maria Concetta|last5=Sorace|first5=Massimo|last6=Cavicchioli|first6=Chiara|last7=Petraglia|first7=Felice|title=A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas|journal=Drug Safety|volume=25|issue=11|year=2002|pages=759–779|issn=0114-5916|doi=10.2165/00002018-200225110-00002}}</ref><ref name="SankaranManyonda2008">{{cite journal|last1=Sankaran|first1=Srividhya|last2=Manyonda|first2=Isaac T.|title=Medical management of fibroids|journal=Best Practice & Research Clinical Obstetrics & Gynaecology|volume=22|issue=4|year=2008|pages=655–676|issn=15216934|doi=10.1016/j.bpobgyn.2008.03.001}}</ref><ref name="Palomba2002">{{cite journal|last1=Palomba|first1=S.|title=Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial|journal=Human Reproduction|volume=17|issue=12|year=2002|pages=3213–3219|issn=14602350|doi=10.1093/humrep/17.12.3213}}</ref><ref name="Golan1996">{{cite journal|last1=Golan|first1=A.|title=GnRH analogues in the treatment of uterine fibroids|journal=Human Reproduction|volume=11|issue=suppl 3|year=1996|pages=33–41|issn=0268-1161|doi=10.1093/humrep/11.suppl_3.33}}</ref>
 
 
 
 




Revision as of 12:08, 20 June 2019

overview

Medical therapy depends on the type of fibroma.

Medical therapy

Uterine fibroma

At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor.[1][2][3][4][5][6][7][8]


Gonadotropin-Releasing Hormone Analogues

Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause. Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin

  1. ↑ Sabry, Mohamed; Al-Hendy, Ayman (2012). "Medical Treatment of Uterine Leiomyoma". Reproductive Sciences. 19 (4): 339–353. doi:10.1177/1933719111432867. ISSN 1933-7191.
  2. ↑ Donnez, Jacques; Dolmans, Marie-Madeleine (2016). "Uterine fibroid management: from the present to the future". Human Reproduction Update. 22 (6): 665–686. doi:10.1093/humupd/dmw023. ISSN 1355-4786.
  3. ↑ Murji, Ally; Whitaker, Lucy; Chow, Tiffany L; Sobel, Mara L (2017). "Selective progesterone receptor modulators (SPRMs) for uterine fibroids". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010770.pub2. ISSN 1465-1858.
  4. ↑ Arena, Saverio; Zupi, Errico (2011). "Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option". Women's Health. 7 (2): 143–146. doi:10.2217/WHE.11.1. ISSN 1745-5065.
  5. ↑ De Leo, Vincenzo; Morgante, Giuseppe; La Marca, Antonio; Musacchio, Maria Concetta; Sorace, Massimo; Cavicchioli, Chiara; Petraglia, Felice (2002). "A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas". Drug Safety. 25 (11): 759–779. doi:10.2165/00002018-200225110-00002. ISSN 0114-5916.
  6. ↑ Sankaran, Srividhya; Manyonda, Isaac T. (2008). "Medical management of fibroids". Best Practice & Research Clinical Obstetrics & Gynaecology. 22 (4): 655–676. doi:10.1016/j.bpobgyn.2008.03.001. ISSN 1521-6934.
  7. ↑ Palomba, S. (2002). "Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial". Human Reproduction. 17 (12): 3213–3219. doi:10.1093/humrep/17.12.3213. ISSN 1460-2350.
  8. ↑ Golan, A. (1996). "GnRH analogues in the treatment of uterine fibroids". Human Reproduction. 11 (suppl 3): 33–41. doi:10.1093/humrep/11.suppl_3.33. ISSN 0268-1161.
Retrieved from "https://www.wikidoc.org/index.php?title=Fibroma_medical_therapy&oldid=1572695"